Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy

Table 1

Clinicopathological characteristics of enrolled patients (n = 105).

	Number (Percentage)	Mean ± Standard deviation
Age	Range: 38~81 y/o	57.69 ± 8.6
Gender:
Male	98 (93.3%)
Female	7 (7.6%)
Pathology
Squamous cell carcinoma	105 (100%)
Tumor site
Upper	28 (26.7%)
Middle	48 (45.7%)
Lower	29 (27.6%)
Stage
I	13 (12.4%)
II	27 (25.7%)
III	65 (61.9%)
Lab data at diagnosis
White blood count (/μL)		7940 ± 2616.9
Hb (g/dL)		13.2 ± 1.77
Platelet count (X10^3/μL)		262.82 ± 110.73
Mean platelet volume (fl)		9.84 ± 0.83
Neutrophil (%)		66.5 ± 11.1
Lymphocyte (%)		23.3 ± 9.5
Monocyte (%)		6.9 ± 2.6
Lab data at finished CCRT
White blood count (/μL)		3845.7 ± 1832.8
Hb (g/dL)		10.9 ± 1.6
Platelet count (X10^3/μL)		174.88 ± 81.1
Mean platelet volume (fl)		9.35 ± 0.92
Neutrophil (%)		79.7 ±11.2
Lymphocyte (%)		9.4 ± 7.9
Monocyte (%)		8.5 ± 5
Chemotherapy cycles
2 cycles	96 (91.4%)
1 cycle	9 (8.6%)
Radiotherapy	105 (100%)
Dose 4000 ~ 5000cGy	40 (38.1%)
Dose > 5000cGy	65 (61.9%)
Post-CCRT response
Complete response	38 (36.2%)
Partial response	48 (45.7%)
Stable disease	2 (1.9%)
Progressive disease	17 (16.2%)
Overall response	86 (81.9%)
Clinical benefit	88 (83.8%)
Post-CCRT treatment
Operation	38 (36.2%)
Chemotherapy	45 (42.9%)
Non-treatment	22 (20.9%)
Expired	56 (53.3%)
Overall survival (days)	(92~1844 days)	586 ± 423.5
Progressive rate	62 (59%)
Time to progressive disease (days)		414.6 ± 355.5
Metastatic rate	56 (53.3%)
Time to metastasis (days)		425.8 ± 356.8